Stevens Johnson syndrome: clinical case report
Article Sidebar
Main Article Content
Abstract
Introduction: Stevens Johnson Syndrome (SJS) is a potentially fatal dermatosis characterized by extensive epidermal and mucosal necrosis accompanied by an attack on the general condition, which together with Toxic Epidermal Necrolysis (TEN) are considered type IV hypersensitivity reactions, related to certain drugs in 60% of cases, being one of the rare diagnoses, but with a high mortality of up to 40%.
Case report: The following clinical case is a 34 year old male who started a generalized erythema picture immediately after administration of the medication trimethoprim/sulfamethoxazole, for which a complete blood count was requested showing leukocytosis, neutrophilia, elevated ESR, elevated PCR, elevated IgE, and after the clinical questioning, the ALDEN algorithm was performed, giving positive with 10 points associated with the previously mentioned medication, for which treatment was started with methylprednisolone, diphenhydramine, intravenous human immunoglobulin and a skin therapeutic plan, resulting in clinical improvement, avoiding complications and sequelae, until the day of discharge. In conclusion, a multidisciplinary management is required to attend to the clinical manifestations of the patient, helping him to a quick and effective recovery.
Article Details
Section
How to Cite
References
Pacheco-Ambriz, D, Félix-Guerrero L, Olivas-Cárdenas G A, Amarillas-Villalvazo A P, Díaz-Amezquita L. Síndrome de Stevens-Johnson asociado con la administración de vacuna Janssen Ad26.COV2.S COVID-19 en Tijuana, Baja California, México. Dermatol Rev Mex. 2021;65(5). doi: https://doi.org/10.24245/dermatolrevmex.v65i5.6913
Barrera-Ochoa CA, Marioni-Manríquez S, Cortázar-Azuaje AM, Quijada-Ucelo ZM, Saba-Mussali AJ, Vega-Memije ME. Tratamiento con inmunoglobulina intravenosa y esteroides sistémicos en pacientes con necrólisis epidérmica tóxica: Experiencia en un hospital en Ciudad de México. Actas Dermo-Sifiliográfica 2022;113(3):294–9. doi: https://doi.org/10.1016/j.ad.2021.08.008
Benedetti J. Síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica (NET) - Trastornos dermatológicos. Manual MSD versión para profesio; 2022.
López DDC, Bautista DKM, Martínez REG, Molina AG. Síndrome de Stevens Johnson necrólisis epidérmica tóxica. An Med Asoc Med Hosp ABC. 2022;67(2):137–41. doi: https://doi.org/10.35366/106029
Liotti L, Caimmi S, Bottau P, Bernardini R, Cardinale F, Saretta F, et al. Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Acta Biomed. 2019;90(3-S):52–60. doi: https://doi.org/10.23750/abm.v90i3-S.8165
Mayorga JS, Jiménez AV, Sánchez ACA. Sindrome de Stevens-Johnson y Necrólisis Epidérmica Tóxica. Revista Medica Sinergia. 2020 Jan 1;5(1):e308–e308. doi: 10.31434/rms.v5i1.308
Paredes-Lascano P, Robalino-Quintana M, Acosta-Acosta E, Bravo-Paredes A, Naranjo-Vázconez G. Síndrome de Stevens-Johnson en edad pediátrica. Revista científica digital INSPILIP. 2018;2(1):1–16.
Instituto Mexicano del Seguro Social. Diagnóstico y Tratamiento del Síndrome de Stevens- Johnson/ Necrólisis Epidérmica Tóxica. México: Instituto Mexicano del Seguro Social; 2011.
Chávez DSF, Carrera JEJ. Síndrome de Steven-Johnson y necrolisis epidérmica toxica: revisión bibliográfic actualizada. Ciencia Latina Revista Científica Multidisciplinar. 2022;6(5):644–61. doi: https://doi.org/10.37811/cl_rcm.v6i5.3105
Park HJ, Yun J, Kang DY, Park J-W, Koh Y-I, Kim S, et al. Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. The Journal of Allergy and Clinical Immunology: In Practice. 2019;7(8):2739-2749.e3. doi: https://doi.org/10.1016/j.jaip.2019.05.047
Zhang AJ, Nygaard RM, Endorf FW, Hylwa SA. Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective review of 10-year experience. Int J Dermatol. 2019;58(9):1069–77. doi: https://doi.org/10.1111/ijd.14409
Arenas-Guzmán R. Síndrome de Stevens-Johnson. In: Dermatología Atlas, diagnóstico y tratamiento,. 6th ed. McGraw Hill; 2015.
Cros A, Borges González S, Estévez Carrizo F. Reacciones adversas medicamentosas graves: síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Revista Médica del Uruguay. 2004;20(3):172–7.
Tsai T-Y, Huang I-H, Chao Y-C, Li H, Hsieh T-S, Wang H-H, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. Journal of the American Academy of Dermatology. 2021;84(2):390–7. doi: https://doi.org/10.1016/j.jaad.2020.08.122
Gaviria-Castellanos JL, Figueroa-Restrepo LG, Gaviria-Castellanos JL, Figueroa-Restrepo LG. Uso de membrana amniótica en el tratamiento de la necrólisis epidérmica tóxica. Caso clínico. Cirugía Plástica Ibero-Latinoamericana. 2022;48(2):199–206. doi: 10.4321/s0376-78922022000200011